This contract expires in 222 days (Dec 2, 2026).
CRITITECH PARTICLE ENGINEERING SOLUTIONS, LLC - DEVELOPMENT OF NOVEL DRUG PARTICLES FOR INHALATIONAL THERAPY
Key Details
Description
DEVELOPMENT OF NOVEL DRUG PARTICLES FOR INHALATIONAL THERAPY
Context & Analysis
On Dec 3, 2025, Department of Defense obligated $140,595.49 to CRITITECH PARTICLE ENGINEERING SOLUTIONS, LLC for development of novel drug particles for inhalational therapy. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: not competed. Performance is located in LAWRENCE, KS. The contract is scheduled through Dec 2, 2026 — approximately 7 months remaining. This award is one of several similar procurements from Department of Defense under NAICS 541715 — related awards are listed below.
Contractor Information
Similar Awards
NAVAL NUCLEAR LABORATORY
FLUOR MARINE PROPULSION, LLC
$14.2B
NAVAL NUCLEAR LABORATORY
FLUOR MARINE PROPULSION, LLC
$13.6B
NEXT GENERATION OVERHEAD PERSISTENT INFRARED GEOSYNCHRONOUS EARTH ORBIT SPACE VEHICLE 1-3 PHASE 1
LOCKHEED MARTIN CORP
$6.3B
NEXT GENERATION OVERHEAD PERSISTENT INFRARED GEOSYNCHRONOUS EARTH ORBIT SPACE VEHICLE 1-3 PHASE 1
LOCKHEED MARTIN CORP
$6.3B
DESIGN, DEVELOPMENT, AND DEVELOPMENTAL TESTING OF THE NEXT GENERATION INTERCEPTOR (NGI) ALL-UP-ROUND (AUR)
LOCKHEED MARTIN CORPORATION
$4.6B
Stay Updated
Get notified about new opportunities matching your interests.